3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
6
Carcinoma, Transitional Cell
6
Carcinoma, Renal Cell
5
Melanoma
4
Non-Muscle Invasive Bladder Neoplasms
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Muscle Invasive Bladder Cancer
2
Mesothelioma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Urothelial Carcinoma Bladder
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Germ Cell Tumor
1
Small Cell Lung Carcinoma
1
Renal Pelvic Carcinoma
1
Pancreatic Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Recurrence, Local
1
Muscle Invasive Bladder Cancer (MIBC)
1
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Nivolumab
2
Gemcitabine
2
Cystectomy
2
Cisplatin
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
tislelizumab
1
relatlimab
1
enzalutamide
1
enfortumab vedotin
1
durvalumab
1
Water
1
Urinary Diversion
1
Standard of Care
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Multiparametric Magnetic Resonance Imaging
1
Microscopy
1
Immunonutrition Diet
1
Immune Checkpoint Inhibitors
1
Gels
1
Fluorouracil
1
Docetaxel
1
Cystoscopy
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Diseases
×
tislelizumab
×
Genitourinary
×
Clear all
NCT04922047
2021-06-11
TACBIN-01
RenJi Hospital
Phase 1/2
Unknown
6 enrolled